HER2 negative MBC trang 1 tải miễn phí từ TAILIEUCHUNG

"HER2 negative MBC" trang 1 - tải miễn phí từ Tailieuchung

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology

13 54 1

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

10 43 1

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review

8 36 1

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

9 35 1

Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype

Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype

12 34 1

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

11 42 1

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis

17 69 0

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

9 80 0

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

11 33 1

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

8 39 1

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016

13 24 1

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

5 68 1

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy

7 27 1

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

12 36 1

Multiple gene aberrations and breast cancer: Lessons from super-responders

Multiple gene aberrations and breast cancer: Lessons from super-responders

6 24 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.